Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;12(2):223-231.
doi: 10.1007/s40487-024-00271-w. Epub 2024 Mar 27.

The Importance of Biomarker Testing in the Treatment of Advanced Non-Small Cell Lung Cancer: A Podcast

Fred R Hirsch  1 , Chul Kim  2
Affiliations

The Importance of Biomarker Testing in the Treatment of Advanced Non-Small Cell Lung Cancer: A Podcast

Fred R Hirsch et al. Oncol Ther. 2024 Jun.

Abstract

The identification of actionable biomarkers and development of targeted therapies have revolutionized the field of lung cancer treatment. In patients with advanced non-small cell lung cancer (NSCLC), biomarker testing can inform selection of effective targeted therapies as well as avoid therapies that are less likely to be effective in certain populations. A growing number of actionable targets, including those involving EGFR, ALK, ROS1, BRAF, MET, KRAS, NTRK, RET, HER2, and PD-L1, can be identified with biomarker testing. More than half of patients with advanced NSCLC have tumors that harbor genetic alterations that can be targeted. When these patients are treated with targeted therapy, survival and quality of life may be significantly improved. In addition, broad-based molecular testing may detect alterations identifying patients who are potentially eligible for current or future clinical trials. Comprehensive biomarker testing rates in communities are often low, and turnaround times for results can be unacceptably long. There is an unmet need for widespread, efficient, and routine testing of all biomarkers recommended by clinical guidelines. New testing techniques and technologies can make this an attainable goal. Panel-based sequencing platforms are becoming more accessible, and molecular biomarker analysis of circulating tumor DNA is becoming more common. In this podcast, we discuss the importance of biomarker testing in advanced NSCLC and explore topics such as testing methodologies, effect of biomarker testing on patient outcomes, emerging technologies, and strategies for improving testing rates in the United States. Supplementary file1 (MP4 121301 KB).

Keywords: Biomarker testing; Non-small cell lung cancer; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Fred Hirsch reports participation on advisory boards for Amgen, AstraZeneca, Blueprint, BMS, G1 Therapeutics, Genentech, Merus, NextCure, Novartis, Novocure, Regeneron, and Sanofi. Chul Kim reports institutional grants from AstraZeneca, BMS, Daiichi Sankyo, Debiopharm, Genentech, Janssen, Karyopharm, Lyell Immunopharma, Novartis, and Regeneron; and consulting fees from Arcus Biosciences, AstraZeneca, Daiichi Sankyo, Diffusion Pharmaceuticals, Eisai, Janssen, Jazz Pharmaceuticals, Mirati, Novartis, PierianDx, Regeneron, and Sanofi.

References

    1. Simeone JC, Nordstrom BL, Patel K, Klein AB. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world US setting. Future Oncol. 2019;15(30):3491–3502. doi: 10.2217/fon-2019-0348. - DOI - PubMed
    1. Camidge DR, Doebele RC, Kerr KM. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019;16(6):341–355. doi: 10.1038/s41571-019-0173-9. - DOI - PubMed
    1. Pennell NA, Arcila ME, Gandara DR, West H. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices. Am Soc Clin Oncol Educ Book. 2019;39:531–542. doi: 10.1200/EDBK_237863. - DOI - PubMed
    1. Aisner DL, Riely GJ. Non-small cell lung cancer: recommendations for biomarker testing and treatment. J Natl Compr Cancer Netw. 2021;19(5.5):610–613. doi: 10.6004/jnccn.2021.5020. - DOI
    1. American Cancer Society. 2023 [cited 2023 January 26]; Available from: https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell/target...